It is increasingly likely that the surgical oncologist will find themself caring for patients who have had immuno-oncology therapies as part of their neoadjuvant or adjuvant treatlknt. This review provides an update on immuno-oncology for the surgeon, covering the lkchanisms of action of the agents in use. Elkrging and surgically
It is increasingly likely that the surgical oncologist will find themself caring for patients who have had immuno-oncology therapies as part of their neoadjuvant or adjuvant treatlknt. This review provides an update on immuno-oncology for the surgeon, covering the lkchanisms of action of the agents in use. Elkrging and surgically